Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
All 10 Pharma-Backed Candidates Grab Upper House Seats
As Japan’s ruling coalition cruised to victory in a parliamentary election on July 10, all 10 candidates supported by the pharmaceutical industry including one opposition member secured their seats in the Upper House. The political arm of the Federation of…
To read the full story
Related Article
- Pharma-Backed Upper House Candidates Kick Off Campaigning for July 10 Poll
June 23, 2022
- “Re-Do” Pricing Based on New Assumption Rather than Simple Cuts, DPP Lawmaker Says on Re-Pricing Rules
June 10, 2022
- Pharmacist LDP Candidate Eager for National Debate on Drug Pricing
June 7, 2022
- Scrap All Barriers, Annual Drug Re-Pricing to Boost International Competitiveness of Japan Pharma: LDP’s Jimi
June 6, 2022
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
- LDP Returnees Set Sights on Social Security, Drug Policy as Special Diet Opens
February 18, 2026
- 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…